Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 Injection in Chinese Healthy Adult Participants

NCT07861581 is registered in ClinicalTrials.gov with Shanghai Qilu Pharmaceutical Research and Development Center LTD as lead sponsor.

NCT NCT07861581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07861581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of QLS2312 Injection in Chinese Healthy Adult Participants
Lead sponsor
Shanghai Qilu Pharmaceutical Research and Development Center LTD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 11, 2026
Completion date
November 20, 2027
Enrollment
70 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants study